Quantum News
Sign InSign Up
Back to News
research

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Catalyst Pharmaceuticals CEO Richard Daly presented at the Barclays Global Healthcare Conference on March 10, 2026, highlighting the company’s focus on ultra-rare disease treatments. The company’s flagship product, FIRDAPSE, treats Lambert-Eaton myasthenic syndrome, a rare neuromuscular disorder, by activating muscle function. AGAMREE, a differentiated steroid, targets Duchenne Muscular Dystrophy, offering a potential alternative to traditional steroid therapies with improved efficacy or safety. Daly emphasized Catalyst’s pipeline of three primary commercial products, each at different lifecycle stages, reinforcing its niche in rare disease therapeutics. The presentation underscored Catalyst’s strategic positioning in underserved markets, aiming to address unmet medical needs with specialized treatments.
AI Audio Summary
0:00 / 0:00
Click to play
f7e9219d-7515-46fb-86c9-f4778fc4627f.jpeg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.9K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Catalyst Pharmaceuticals, Inc. (CPRX) Barclays 28th Annual Global Healthcare Conference March 10, 2026 3:30 PM EDT Company Participants Richard John Daly - President, CEO & Director Conference Call Participants Glen Santangelo - Barclays Bank PLC, Research Division Presentation Glen SantangeloBarclays Bank PLC, Research Division Okay. Good afternoon, everyone. Thank you for taking the time to join us here. For our next presentation, we're excited to have Catalyst Pharmaceuticals. And joining me from the company to my left is Rich Daly, who's the Chief Executive Officer of the company. For those of you who don't know me, I'm Glen Santangelo. I'm one of the Life Sciences Analysts at Barclays. I cover spec pharma and animal health. We do not cover Catalyst Pharmaceuticals, but it's been interesting to learn a lot about it in the past several weeks. So really looking forward to the presentation. So thank you, Rich, for joining us. Very glad to have you here.

Richard John DalyPresident, CEO & Director Thanks, Glen. Glen SantangeloBarclays Bank PLC, Research Division Maybe a good place for us to start for those who don't know the company, maybe we should just spend a minute or 2 talking about your 3 primary commercial products are in different stages of their life cycle. Maybe just sort of give a high-level overview of the company for a minute or 2, and then we can sort of dive right in.

Richard John DalyPresident, CEO & Director No problem.

So Catalyst Pharmaceuticals is a company focused on rare diseases. And in our rare disease portfolio, it's actually ultra-rare. So we have a muscle activating drug called FIRDAPSE which works in Lambert-Eaton myasthenic syndrome. And then we also have a drug for Duchenne Muscular Dystrophy. It's a steroid, we believe a differentiated steroid called the AGAMREE. And FIRDAPSE has been on

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.